TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10806764
Drug: Nao Yi-an
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nao Yi-an granule (Chinese medicine group, CMG)
Study: 10806764
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (western medicine group, WMG)
Study: 2575983
Drug: nifedipine 20mg
Normalized name: NIFEDIPINE 20MG CAP
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine 20mg twice daily
Study: 28701090
Drug: Transference Focused
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transference Focused Psychotherapy (TFP) combined with group skills training from Dialectic Behavior Therapy (DBT)
Study: 26553085
Drug: Intravenous Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Dexamethasone (8 mg)
Study: 26553085
Drug: Control (distilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (distilled water, 8 mg)
Study: 22279697
Drug: Literal adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literal adherence for pharmacotherapy initiations
Study: 22279697
Drug: Literal adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literal adherence for drug up-titrations
Study: 22279697
Drug: Substitute adherence
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitute adherence for drug up-titrations
Study: 16490876
Drug: 200-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-microg dose of mometasone furoate nasal spray administered once daily
Study: 16490876
Drug: 200-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-microg dose of mometasone furoate nasal spray administered twice daily
Study: 16490876
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered in the morning and evening
Study: 15214595
Drug: Systemically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically administered 5-FU
Study: 15214595
Drug: HAI chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI chemotherapy
Study: 11141713
Drug: Preventive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive management (0.45% saline intravenously, mannitol 20% 250 mL i.v., furosemide 80 mg i.v., dopamine 3 g/Kg/min i.v.)
Study: 16250725
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment package
Study: 7930276
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/day (increased to 10 mg/day after 4 weeks)
Study: 2843341
Drug: Lisinopril +
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril + HCTZ
Study: 2843341
Drug: All other
Normalized name: ALL OTHER THERAPEUTIC PRODUCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All other agents
Study: 31635497
Drug: BCX7353 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX7353 (oral plasma kallikrein inhibitor), taken as an oral capsule, once daily.
Study: 29231583
Drug: Acupoint plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint plaster therapy with midnight-noon ebb-flow hour-prescription method
Study: 29231583
Drug: Traditional acupoint
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional acupoint plaster therapy
Study: 19200622
Drug: Tamsulosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin plus ibuprofen and oxycodone
Study: 19200622
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and oxycodone alone
Study: 17405199
Drug: Transdermal anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal anaesthesia using EMLA applied transcutaneously 120 minutes prior to the operation (Group A)
Study: 17405199
Drug: Transdermal anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal anaesthesia using EMLA (Group A)
Study: 10991932
Drug: L-NAME, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME, 1 micromol per nostril every 30 min for 6 h
Study: 10991932
Drug: L-arginine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine, 30 micromol
Study: 10991932
Drug: L-NMMA, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA, 1 micromol
Study: 10991932
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of L-NAME, 1 micromol
Study: 3468098
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin
Study: 3546155
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ofloxacin
Study: 29777864
Drug: Home‐based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home‐based dietary counseling +800 mg/day DHA supplementation
Study: 29777864
Drug: 800 mg/day DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day DHA
Study: 29777864
Drug: Home‐based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home‐based dietary counseling +200 mg/day DHA
Study: 29777864
Drug: 200 mg/day DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day DHA
Study: 24939437
Drug: α-Lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-Lipoic acid (ALA) (100 mg/day)
Study: 21992977
Drug: Lactobacillus crispatus
Normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus crispatus CTV-05 (LACTIN-V) applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Study: 21992977
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Study: 21992977
Drug: Endogenous L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous L. crispatus presence
Study: 14634680
Drug: PEG‐OB protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐OB protein (80 mg) administered subcutaneously weekly for 6 weeks
Study: 14634680
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously weekly for 6 weeks
Study: 14634680
Drug: PEG‐OB protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐OB protein (80 mg)
Study: 8877657
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Braun/Oral-B Plak Control)
Study: 6109119
Drug: Dry artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry artificial lung surfactant (one dose)
Study: 26370443
Drug: 600 mcg
Normalized name: Biotin 600 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg misoprostol
Study: 23469256
Drug: Pregabalin (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150-300 mg BID)
Study: 21441812
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) in combination with a probiotic
Study: 15513446
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG) combined with feeder vessel treatment (FVT)
Study: 15513446
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG)
Study: 28271568
Drug: Ziziphus jujube
Normalized name: Ziziphus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziziphus jujube fruit (ZJF) infusion (10 g/100 mL boiling water) three times/day before main meals for 12 weeks
Study: 20528210
Drug: Flutamide-metformin
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide-metformin
Study: 20528210
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with ethinylestradiol-drospirenone and flutamide-metformin
Study: 18931625
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (IT) - fixed 8‐week off, 8‐week on regimen
Study: 18931625
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment (CT) - maintain current treatment strategy
Study: 18931625
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment (CT)
Study: 16820341
Drug: CGA (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGA (140 mg/day) from green coffee bean extract
Study: 14968473
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of elemental zinc for 3 months
Study: 1590494
Drug: Focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused cognitive therapy for 12 weeks
Study: 1590494
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to focused cognitive therapy for 12 weeks
Study: 6084394
Drug: 2.5% phenylpropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% phenylpropanolamine (PPA) solution
Study: 26515839
Drug: Twice-weekly targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly targeted ultraviolet B phototherapy
Study: 26515839
Drug: Once-weekly targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly targeted ultraviolet B phototherapy
Study: 24229746
Drug: Memantine (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (flexible dose 5-20 mg/d, all reaching 20 mg/d)
Study: 15022581
Drug: Dexamethasone for
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone for five days (12 mg single dose)
Study: 15022581
Drug: Dexamethasone less
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone less than five days (12 mg single dose)
Study: 10964582
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (Neoral), administered once, dosage not specified
Study: 10964582
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered once, matching CsA
Study: 1308265
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + Gentamycin postoperatively
Study: 3872001
Drug: Alcuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.25 mg X kg b.w.‐1 with high-dose fentanyl
Study: 3872001
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg X kg b.w.‐1 with high-dose fentanyl
Study: 3872001
Drug: Alcuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.25 mg X kg b.w.‐1 with balanced anaesthesia
Study: 3872001
Drug: Pancuronium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.05 mg X kg b.w.‐1 + alcuronium 0.125 mg X kg b.w.‐1
Study: 3872001
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg X kg b.w.‐1
Study: 3872001
Drug: Alcuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.25 mg X kg b.w.‐1
Study: 28840591
Drug: Regular drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular drug-eluting stents (rDES)
Study: 25215468
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplementation (arginine, glutamine, HMB) twice daily for 2 weeks
Study: 20059663
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy treatment (manual therapy, biofeedback, electrical stimulation, dilator insertions, and home exercises) for women with PVD after 8 sessions
Study: 17512098
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 23 valent pneumococcal vaccine
Study: 17512098
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 23 valent pneumococcal vaccine
Study: 17512098
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection compared to intramuscular injection
Study: 17512098
Drug: Pre‐vaccination antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐vaccination antibody titres >1 microg/ml
Study: 17512098
Drug: Female gender
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Female gender with subcutaneous injection
Study: 11824861
Drug: COER-24 verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER-24 verapamil 240 mg/day titrated to 360 mg/day
Study: 11824861
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg/day titrated to 20 mg/day
Study: 11824861
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/day titrated to 100 mg/day
Study: 11008892
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg b.i.d. oral nilvadipine for 4 weeks
Study: 8618108
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (AMC) 500/125mg tid for 7 days
Study: 8618108
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (AMC)
Study: 6101610
Drug: Psychotropic substances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic substances (initial standard dose)
Study: 30644628
Drug: Intranasal 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 1.4 mg naloxone (two doses)
Study: 30644628
Drug: Intranasal 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 1.4 mg naloxone vs Intramuscular 0.8 mg naloxone
Study: 19864452
Drug: Saxagliptin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (2.5 mg) plus TZD
Study: 19864452
Drug: Saxagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (5 mg) plus TZD
Study: 17925592
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg daily
Study: 10728939
Drug: alpha‐streptococcal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐streptococcal spray treatment
Study: 10728939
Drug: placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo spray treatment
Study: 7536871
Drug: Filgrastim treatment
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim treatment for neutrophil recovery
Study: 31025259
Drug: In ovo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ovo injection of 1 × 10^9 CFU B. bifidum
Study: 31025259
Drug: In ovo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ovo injection of 1 × 10^7 CFU B. bifidum
Study: 31025259
Drug: In ovo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ovo injection of 1 × 10^9 CFU B. longum
Study: 31025259
Drug: In ovo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ovo injection of 1 × 10^7 CFU B. longum
Study: 31025259
Drug: Intact (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact (without injection) control group
Study: 31025259
Drug: In ovo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ovo injection of bifidobacteria strains
Study: 28057659
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 at a dose of 108 colony-forming units, orally, twice daily during antibiotic treatment
Study: 28057659
Drug: Placebo, identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identically appearing, orally, twice daily during antibiotic treatment
Study: 25527751
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with added protein (61.5% of energy from fat; 51.1 ± 7.9 g of protein; 191.9 ± 9.9 kcal added)
Study: 21505892
Drug: L-thyroxin (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxin (L-T4) therapy
Study: 18486783
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment of nondisplaced, nondislocated fractures (Classes I and VI)
Study: 16841627
Drug: Pregabalin 400
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 400 mg/day
Study: 10807491
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg/day
Study: 12920975
Drug: Volume Guarantee
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Guarantee (VG) set at 5 ml/Kg
Study: 12920975
Drug: Volume Guarantee
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Guarantee (VG) set at 3 ml/Kg
Study: 7498858
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of verapamil retard (240 mg) and hydrochlorothiazide (12.5 mg)
Study: 7498858
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with verapamil or hydrochlorothiazide
Study: 2258338
Drug: Pefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (400 mg twice daily, orally)
Study: 2258338
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g twice daily, iv)
Study: 6780235
Drug: Proxicromil (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxicromil (18 mg twice per day for the first 3 weeks, then 18 mg four times per day for the next 3 weeks)
Study: 26809868
Drug: IgG4-guided exclusion
Normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IgG4-guided exclusion diet (excluding four food types with the highest antibody titers for 4 weeks)
Study: 26809868
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (excluding four foods with the lowest antibody titers)
Study: 23244537
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FO) 1 g twice a day for 120 days
Study: 23244537
Drug: Placebo (mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mineral oil) 1 g twice a day for 120 days
Study: 17932317
Drug: Rosiglitazone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (20 mg/kg/d)
Study: 7599015
Drug: Erythromycin 1.5
Normalized name: ERYTHROMYCIN 1.5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1.5 g
Study: 29570454
Drug: Repeat/second cesarean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat/second cesarean with ultrasound-guided intervention (Int-G)
Study: 29570454
Drug: Second cesarean
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second cesarean utilizing the usual procedure (CS2-G)
Study: 28851407
Drug: Second 1000-ml
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second 1000-ml fluid bolus (standard care)
Study: 28851407
Drug: Maintenance rate
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance rate fluid only with early commencement of a vasopressor infusion
Study: 25103924
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) treatment
Study: 22021620
Drug: Raltegravir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir treatment intensification
Study: 22021620
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment augmentation (Control)
Study: 16466830
Drug: Pre- to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- to post-weight loss treatment
Study: 9223393
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glimepiride daily for 7 days and 10 mg prior to a hyperglycaemic clamp
Study: 27101556
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg saffron capsule (Crocus sativus L. stigma) twice daily for 12 weeks
Study: 27101556
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule twice daily for 12 weeks
Study: 21801467
Drug: Lingzhi (Ganoderma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingzhi (Ganoderma lucidum) 1.44 g daily for 12 weeks
Study: 20842389
Drug: CSII with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII with insulin analogues
Study: 15718180
Drug: Nurse-led intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led intervention involving patient and family education about heart failure and self-management, and monthly telephone follow-up during 12 months by a primary health care nurse
Study: 8671790
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (1 ng.kg-1.min-1)
Study: 8671790
Drug: CsA ingestion
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA ingestion (3 mg.kg-1)
Study: 8671790
Drug: Control clearance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control clearance study without CsA intake or iloprost/placebo infusion
Study: 1877813
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy (IA)
Study: 1877813
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (IV)